Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial: sciencedirect.com/science/articl…. The results of our #psilocybin-assisted therapy for #depression study are published.
If you don’t feel like reading the entire article during your winter break, here is a brief summary:
A single dose of psilocybin in combination with psychological support significantly decreased symptom severity in a group of MDD patients compared to patients who received psychological support and a placebo.
Rapid and enduring (assessed up to 2 weeks after administration) antidepressant effects were observed in the psilocybin-assisted therapy group.
Importantly, the dose administered in this study was lower (0.215 mg/kg body weight) than the effective doses used in most previous trials, and it was only administered once.
That said, as in previous trials, psychedelic-assisted therapy worked better for some patients than for others. In the future we will need to better understand this heterogeneity (a previous article on this topic is published here: sciencedirect.com/science/articl…).
In this trial, subjective drug-induced effects were not strongly associated with treatment response.
While the results of the present study suggest that a single, moderate dose of psilocybin may be as efficacious in reducing depressive symptoms as the repeated higher doses administered in previous studies, our study also has limitations and many open questions ...
...(e.g., blinding, expectancy) remain to be addressed in future work.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
